Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase™ platform gene editors to build a pipeline of treatments for serious genetic diseases. Toronto, Ontario, Canada [December…
Read More
Functional selectivity of GPCR signaling and its spatio-temporal propagation; Toward the design of better drugs? Join us for adMare’s Industry Builder Webinar Series, featuring Dr. Michel Bouvier. Dr. Bouvier…
A new made-in-Canada life sciences company, NIMIUM Therapeutics, has been launched to develop novel therapies for patients with cardiometabolic diseases. The company’s foundational technology is based on the cutting-edge research…
A key part of CDRD’s Mission is training the next generation of highly-qualified personnel to drive the development of new innovations. Visit our YouTube Channel to meet some of the…
Sepset’s initiation of a clinical study is a significant step forward in commercializing a test for health care professionals so they can rapidly and appropriately treat a condition where minutes are the difference between life and death. Current methods to diagnose sepsis take more than 24 hours by which time patients are often well on their way towards tissue damage, organ failure, and death.
